6 patient evaluations for ALS Phase 3 Study Dexpramipexole (KNS-760704)

Sort by: Most recent

Jan 16, 2013 (Started Aug 24, 2011)

  • Effectiveness
    Can't tell (for amyotrophic lateral sclerosis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 300 mg Daily
Cost: < $25 monthly

Nov 26, 2012 (Started Aug 24, 2011)

  • Effectiveness
    Major (for amyotrophic lateral sclerosis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 300 mg Daily
Advice & Tips: Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Phasellus faucibus turpis sed mi maximus mattis.
Cost: < $25 monthly
  • 0 helpful marks

Oct 11, 2012 (Started Jun 16, 2011)

  • Effectiveness
    Can't tell (for Participate in clinical trial)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Dosage: 300 mg Daily
Advice & Tips: Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Phasellus faucibus turpis sed mi maximus mattis.
  • 0 helpful marks

Oct 10, 2012 (Started Sep 10, 2011)

  • Effectiveness
    Can't tell (for Participate in clinical trial)
  • Effectiveness
    Can't tell (for amyotrophic lateral sclerosis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 2 Daily
  • 0 helpful marks
Last updated:
Showing 3 of 6 patient evaluations for ALS Phase 3 Study Dexpramipexole (KNS-760704)
See more data on ALS Phase 3 Study Dexpramipexole (KNS-760704)